Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Locteron vs PEG-Intron in Treatment-Naïve HCV Genotype 1
NCT00953589Phase 2Completed
- Sponsor
- Biolex Therapeutics
- Start
- Jul 2009
- Primary completion
- May 2010
- Modality
- Cytokines & Interferons
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of Interferon alfa-2b vaginal effervescent tablet in hepatitis C (HCV), sponsored by Biolex Therapeutics. Primary endpoint: Early Virologic Response at 12 weeks. Started Jul 2009; status: completed.
02
Drugs
Interferon alfa-2b vaginal effervescent tablet
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00953589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953589.